KR102491188B1 - Manufacturing method of the strawberry stem extracts and Anti-oxidant and anti-inflammatory composition, Health functional foods containing the same and Cosmetics using the same - Google Patents
Manufacturing method of the strawberry stem extracts and Anti-oxidant and anti-inflammatory composition, Health functional foods containing the same and Cosmetics using the same Download PDFInfo
- Publication number
- KR102491188B1 KR102491188B1 KR1020210179088A KR20210179088A KR102491188B1 KR 102491188 B1 KR102491188 B1 KR 102491188B1 KR 1020210179088 A KR1020210179088 A KR 1020210179088A KR 20210179088 A KR20210179088 A KR 20210179088A KR 102491188 B1 KR102491188 B1 KR 102491188B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- measured
- equation
- expression rate
- absorbance
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 109
- 235000011363 Fragaria x ananassa Nutrition 0.000 title claims abstract description 91
- 235000016623 Fragaria vesca Nutrition 0.000 title claims abstract description 90
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 15
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 14
- 239000000203 mixture Substances 0.000 title claims abstract description 12
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 11
- 239000002537 cosmetic Substances 0.000 title claims abstract description 11
- 235000013376 functional food Nutrition 0.000 title claims abstract description 8
- 230000036541 health Effects 0.000 title claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 title claims description 10
- 235000006708 antioxidants Nutrition 0.000 title description 8
- 240000009088 Fragaria x ananassa Species 0.000 title description 2
- 241000220223 Fragaria Species 0.000 claims abstract description 95
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 53
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims description 41
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims description 41
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 38
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims description 38
- 238000002835 absorbance Methods 0.000 claims description 37
- 239000013642 negative control Substances 0.000 claims description 31
- 230000002292 Radical scavenging effect Effects 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 28
- 230000005764 inhibitory process Effects 0.000 claims description 24
- 239000002158 endotoxin Substances 0.000 claims description 22
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 22
- 238000005259 measurement Methods 0.000 claims description 22
- 238000002156 mixing Methods 0.000 claims description 13
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 235000013824 polyphenols Nutrition 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000003260 vortexing Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 claims 8
- 125000004432 carbon atom Chemical group C* 0.000 abstract description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 60
- 210000004027 cell Anatomy 0.000 description 16
- 239000000469 ethanolic extract Substances 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 9
- 235000013399 edible fruits Nutrition 0.000 description 7
- 230000006378 damage Effects 0.000 description 6
- 235000021012 strawberries Nutrition 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- ABVCUBUIXWJYSE-WVXKDWSHSA-O (2s,3r,4s,5r,6r)-2-[5,7-dihydroxy-2-(4-hydroxyphenyl)chromenylium-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC=C(O)C=C1 ABVCUBUIXWJYSE-WVXKDWSHSA-O 0.000 description 2
- CETWDUZRCINIHU-UHFFFAOYSA-N 2-heptanol Chemical compound CCCCCC(C)O CETWDUZRCINIHU-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000008049 biological aging Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 210000004177 elastic tissue Anatomy 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- DSNCQKUYZOSARM-LFHLZQBKSA-N 1-p-Cumaroylglucose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(=O)C=CC1=CC=C(O)C=C1 DSNCQKUYZOSARM-LFHLZQBKSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- XFZJEEAOWLFHDH-HNTGQZGLSA-N Procyanidin B3 Natural products C1([C@@H]2[C@@H](O)[C@@H](C3=C(O)C=C(O)C=C3O2)C=2C(O)=CC(O)=C3C[C@@H]([C@@H](OC3=2)C=2C=C(O)C(O)=CC=2)O)=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-HNTGQZGLSA-N 0.000 description 1
- 229920000236 Procyanidin B3 Polymers 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- RRZGGCNIIVPLCJ-YCUKXQBPSA-N Quercetin 7-xyloside Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@H](O)CO1)c1cc(O)c2C(=O)C(O)=C(c3cc(O)c(O)cc3)Oc2c1 RRZGGCNIIVPLCJ-YCUKXQBPSA-N 0.000 description 1
- RRZGGCNIIVPLCJ-ZFXLMXADSA-N Quercetin 7-xyloside Chemical compound OC1[C@@H](O)[C@H](O)CO[C@H]1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 RRZGGCNIIVPLCJ-ZFXLMXADSA-N 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000009045 body homeostasis Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- HLNRBHDRGMNBEG-UHFFFAOYSA-N nitrous acid Chemical compound ON=O.ON=O HLNRBHDRGMNBEG-UHFFFAOYSA-N 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- XFZJEEAOWLFHDH-AVFWISQGSA-N procyanidin B3 Chemical compound C1([C@@H]2[C@@H](O)[C@@H](C3=C(O)C=C(O)C=C3O2)C=2C(O)=CC(O)=C3C[C@@H]([C@H](OC3=2)C=2C=C(O)C(O)=CC=2)O)=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-AVFWISQGSA-N 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2132—Other phenolic compounds, polyphenols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 미성숙 딸기 과육의 추출물을 이용한 항산화 및 항염증성 조성물, 이를 이용한 건강기능식품 및 화장료에 관한 발명이다.The present invention relates to an antioxidant and anti-inflammatory composition using an extract of immature strawberry pulp, and to health functional foods and cosmetics using the same.
인간은 시간이 흐름에 따라 생리적 기능이 저하되는 노화 현상을 경험하게 되고, 생체적인 노화 정도를 판단할 수 있는 지표가 되는 것 중 하나가 피부이다. 피부는 인체의 일차 방어막으로서 체내의 제기관을 온도 및 습도 변화와 자외선, 공해물질 등 외부환경의 자극으로부터 보호해주며, 체온조절 등의 생체 항상성 유지에 중요한 역할을 하고 있다. 피부는 외부환경에 항상 노출되어 있으므로 노화에 따른 피부변화는 많은 부분이 외부인자들의 영향에 의한 것이라고 할 수 있다. 특히 외부 인자에 대한 염증 반응, 활성산소, 자외선 등이 주요 원인으로 간주되고 있다.Humans experience an aging phenomenon in which physiological functions deteriorate over time, and one of the indicators that can determine the degree of biological aging is the skin. Skin, as the primary barrier of the human body, protects various organs in the body from changes in temperature and humidity, ultraviolet rays and pollutants from the external environment, and plays an important role in maintaining body homeostasis such as regulating body temperature. Since the skin is always exposed to the external environment, it can be said that many of the skin changes due to aging are due to the influence of external factors. In particular, inflammatory reactions to external factors, active oxygen, and ultraviolet rays are considered to be the main causes.
활성산소는 피부세포 및 조직 손상을 주도하여 항산화 방어체계를 파괴하여 생체 노화뿐 아니라 피부노화에 관여하고 있으며 여러 장기에 기능적 손상을 입힘으로써 여러 질병을 유발하고 노화를 촉진시킨다. 또한 지속적인 산화스트레스로 인해 단백질 분해효소의 활성화, 탄력섬유인 콜라겐과 엘라스틴 절단, 히아루론산 절단 등의 생 체 구성 성분들의 손상을 야기시키며 피부 염증 유발 및 피부 면역기능을 억제시켜 세균 감염증 또는 발암율의 증가를 가져온다.Active oxygen is involved in skin aging as well as biological aging by destroying the antioxidant defense system by leading skin cell and tissue damage, and causes various diseases and accelerates aging by causing functional damage to various organs. In addition, continuous oxidative stress causes damage to biocomponents such as activation of proteolytic enzymes, cutting of collagen and elastin, which are elastic fibers, and cutting of hyaluronic acid. bring
염증반응은 체내에 기질적 변화를 가져오는 화학적 물질, 세균 감염 및 물리적 작용에 의해 발생된 손상 부위를 재생하려는 기전으로, 이러한 염증반응은 유해한 자극, 감염 및 외상 등에 의한 염증이 발현되면 국소적으로 염증성 성분과 같은 혈관 활성물질이 유리되어 유발되며, 이와 같은 염증반응이 지속되면 오히려 점막손상을 촉진함에 따라 발적, 발열, 종창, 동통, 기능장애 등의 여러 질환을 발생시키는 원인이 된다. 피부에 있어 염증반응의 결과로 분비되는 효소들은 주변 세포나 조직을 파괴하고 손상시키게 되고, 이로 인해 피부의 콜라겐 섬유 및 탄력 섬유가 파괴되는 등 피부 노화의 원인이 된다. 따라서 각종 피부 노화 원인으로부터 피부를 지키기 위해서는 활성산소를 억제하고 피부 자극 및 염증을 완화하여 피부를 진정시키고 보호하여야 한다.Inflammatory response is a mechanism to regenerate damaged areas caused by chemical substances, bacterial infections, and physical actions that cause organic changes in the body. It is caused by the release of vasoactive substances such as inflammatory components, and if such an inflammatory reaction continues, it rather promotes mucosal damage, thereby causing various diseases such as redness, fever, swelling, pain, and functional disorders. Enzymes secreted as a result of an inflammatory reaction in the skin destroy and damage surrounding cells or tissues, which causes skin aging such as destruction of collagen fibers and elastic fibers of the skin. Therefore, in order to protect the skin from various causes of skin aging, it is necessary to soothe and protect the skin by suppressing active oxygen and alleviating skin irritation and inflammation.
재배 딸기(Fragaria ananassa Duch.)는 장미과에 속하는 다년생 식물로 재배 기간이 길고 노동력이 많이 드는 작물에 속하지만 저온에서 생육이 가능하며 저가온 시설재배로 11월부터 5월까지 수확할 수 있다. 재배딸기에는 플라보노이드(flavonid)류로 퀘르세틴-7-자일로사이드(quercetin-7-xyloside), 프라가린(fragarin), 프로시아니딘 B3(procyanidin B3), 1-O-p-쿠마로일글루코스(1-O-p-coumaroylglucose), 2-헵탄올(2-heptanol) 또는 엘라직산(ellagic acid) 등을 포함하는 것으로 알려져 있다. 이에 딸기를 이용한 항염, 항암, 신장질환 등 질환 관련 많은 연구들이 다수 진행되고 있다. 또한, 향기와 색상이 우수하여 현재 잼, 시럽, 주스 등의 제조 원료로 많이 사용되고 있으며, 이를 이용한 가공품 가치도 높아 관련 연구들도 많이 진행되어 있는 상태이다. 딸기를 이용한 다양한 항산화제, 항염증제 관련 연구 및 관련 상품 개발이 지속되고 있으나, 소비자 만족을 충족시킬만한 상품 개발이 미진한 실정이다.Cultivated strawberry (Fragaria ananassa Duch.) is a perennial plant belonging to the Rosaceae family that has a long cultivation period and is a labor-intensive crop, but can be grown at low temperatures and can be harvested from November to May through low-temperature facility cultivation. Cultivated strawberries contain flavonoids such as quercetin-7-xyloside, fragarin, procyanidin B3, and 1-O-p-coumaroylglucose. ), 2-heptanol or ellagic acid. As a result, many studies on diseases such as anti-inflammatory, anti-cancer, and kidney diseases using strawberries are being conducted. In addition, because of its excellent fragrance and color, it is currently used as a raw material for manufacturing jams, syrups, juices, etc. Research on various antioxidants and anti-inflammatory agents using strawberries and development of related products are continuing, but product development that satisfies consumer satisfaction is insufficient.
본 발명은 낙과 또는 날씨 피해로 인해 성숙되지 못한 미성숙 딸기 과실을 가공한, 항산화성 및 항염증성 유효성분을 다량 함유한 추출물을 제공하고자 한다.The present invention is to provide an extract containing a large amount of antioxidant and anti-inflammatory active ingredients processed from immature strawberry fruits that have not matured due to fallen fruit or weather damage.
또한, 본 발명은 상기 추출물을 이용한 건강기능식품, 화장료를 제공하고자 한다.In addition, the present invention is to provide a health functional food, cosmetics using the extract.
상술한 과제를 해결하기 위한, 본 발명의 항산화성 및 항염성 조성물은 미성숙 딸기 과육 추출물을 유효성분으로 포함하며, 상기 미성숙 딸기 과육 추출물은 탄소수 1 ~ 4의 저급 알코올 추출물이다.In order to solve the above problems, the antioxidant and anti-inflammatory composition of the present invention contains immature strawberry pulp extract as an active ingredient, and the immature strawberry pulp extract is a lower alcohol extract having 1 to 4 carbon atoms.
또한, 본 발명은 미성숙 딸기 과육 추출물의 제조방법에 관한 것으로서, 미성숙 딸기 과육을 세척 및 건조시킨 후, 분쇄하여 딸기 분말을 준비하는 1단계; 상기 딸기 분말 및 탄소수 1 ~ 4의 저급 알코올 수용액을 혼합한 후, 20 ~ 30℃에서 18 ~ 30시간 동안 교반을 수행하는 2단계; 2단계를 수행한 추출액을 여과하여 상등액과 침전물을 분리하는 3단계; 상등액을 진공감압농축을 수행하여 농축물을 수득한 후, 동결건조를 수행하여 알코올 추출물을 수득하는 4단계;를 포함하는 공정을 수행하여 제조할 수도 있다.In addition, the present invention relates to a method for preparing an immature strawberry pulp extract, comprising the steps of preparing strawberry powder by washing and drying the immature strawberry pulp and then pulverizing it; A second step of mixing the strawberry powder and the lower alcohol aqueous solution having 1 to 4 carbon atoms and then stirring at 20 to 30 ° C. for 18 to 30 hours; Step 3 of separating the supernatant and the precipitate by filtering the extract obtained in
본 발명의 미성숙 딸기 과육 추출물은 낮은 세포독성을 가지고, 다량의 폴리페놀을 함유하고 있는 바, 전자공여능 활성 및 ABTS 라디칼 소거능이 우수하여 항산화성이 우수하며, NO 생성 억제 및 iNOS와COX-2 단백질 발현을 억제하여 항염증성이 우수하며, 버려지던 딸기의 낙과, 미성숙 딸기 과실을 활용함으로써 딸기 농가의 수익 증대에 도움을 줄 수 있다.The immature strawberry pulp extract of the present invention has low cytotoxicity and contains a large amount of polyphenols, so it has excellent electron donating activity and ABTS radical scavenging activity, so it has excellent antioxidant properties, inhibits NO production and iNOS and COX-2 proteins It has excellent anti-inflammatory properties by suppressing expression, and it can help increase the profits of strawberry farmers by utilizing discarded strawberry fruits and immature strawberry fruits.
도 1은 실험예 1에서 실시한 미성숙 딸기 과육 에탄올 추출물의 전자공여능(DPPH assay, 1-1-diphenyl-2-picryl-hydrazyl) 측정 결과이다.
도 2은 실험예 1에서 실시한 미성숙 딸기 과육 에탄올 추출물의 ABTS(2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid) 라디칼 소거능 측정 결과이다.
도 3은 실험예 2에서 실시한 세포 독성(또는 세포 생존율) 측정 결과이다.
도 4는 실험예 3에서 실시한 NO 생성 저해 측정 결과이다.
도 5는 실험예 4에서 실시한 iNOS 및 COX-2 단백질 발현 저해 측정 결과이다.1 is a result of measuring electron donating ability (DPPH assay, 1-1-diphenyl-2-picryl-hydrazyl) of immature strawberry pulp ethanol extracts performed in Experimental Example 1.
2 is a result of measuring ABTS (2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid) radical scavenging activity of immature strawberry pulp ethanol extracts performed in Experimental Example 1.
3 is a result of measuring cytotoxicity (or cell viability) performed in Experimental Example 2.
4 is a result of NO production inhibition measurement conducted in Experimental Example 3.
5 is a result of measuring inhibition of iNOS and COX-2 protein expression conducted in Experimental Example 4.
이하에서 본 발명의 항산화 및 항염성 조성물 소재인 미성숙 딸기 과육 추출물을 제조하는 방법을 통해서 본 발명을 더욱 자세하게 설명한다.Hereinafter, the present invention will be described in more detail through a method for preparing the unripe strawberry pulp extract, which is a material for the antioxidant and anti-inflammatory composition of the present invention.
본 발명은 미성숙 딸기 과육(또는 딸기 미성숙과)를 이용하여, 미성숙 딸기딸기 과육이란, '채 익지 않은 과일’을 뜻하는 순 우리말로 똘기를 말한다. 딸기의 적정 수확 시기는 착색 정도에 따라 결정되며, 딸기의 생육 시기 중 미성숙기는 과실의 착색 정도가 일어나지 않은 상태로서 과실은 착색되지 않은 부분이 다소 짙거나 옅은 녹색을 지니고, 크기가 1.0 ~ 2.0cm 정도 되는 어린 딸기로 분류하여 미성숙기라고 한다.The present invention uses immature strawberry pulp (or immature strawberry), and immature strawberry pulp refers to a pure Korean word for 'unripe fruit'. The proper harvesting time of strawberries is determined by the degree of coloration, and the immature period during the growth period of strawberries is a state in which the degree of coloration of the fruit has not occurred. It is classified as a young strawberry of about 30 years old and is called immature.
본 발명의 미성숙 딸기 과육 추출물은 딸기 미성숙과의 알코올 추출물일 수 있다.The pulp extract of immature strawberry of the present invention may be an alcohol extract of immature strawberry.
미성숙 딸기 과육 알코올 추출물은 미성숙 딸기 과육(딸기 미성숙과)를 세척 및 건조시킨 후, 분쇄하여 딸기 분말을 준비하는 1단계; 상기 딸기 분말 및 알코올 수용액을 혼합한 후, 20 ~ 30℃, 바람직하게는 22 ~ 27℃에서 18 ~ 30시간 동안 교반을 수행하는 2단계; 2단계를 수행한 추출액을 여과하여 상등액과 침전물을 분리하는 3단계; 및 상등액을 진공감압농축을 수행하여 농축물을 수득한 후, 동결건조를 수행하여 알코올 추출물을 수득하는 4단계;를 포함하는 공정을 수행하여 제조할 수 있다.Immature strawberry pulp alcohol extract is prepared by preparing strawberry powder by washing and drying immature strawberry pulp (immature strawberry) and then pulverizing; After mixing the strawberry powder and the aqueous alcohol solution, a second step of performing stirring at 20 to 30 ° C, preferably 22 to 27 ° C for 18 to 30 hours; Step 3 of separating the supernatant and the precipitate by filtering the extract obtained in
알코올 추출물 제조공정의 1단계에서 상기 알코올 수용액은 탄소수 1 ~ 4의 저급 알코올 수용액을 사용할 수 있고, 바람직하게는 에탄올 수용액일 수 있으며, 더욱 바람직하게는 65 ~ 80 부피% 농도의 에탄올 수용액을 사용할 수 있다. 에탄올 수용액 사용시 에탄올 수용액의 농도가 65 부피% 미만이면 추출액 내 생리활성 유효성분 함량이 낮을 수 있고, 농도가 80 부피%를 초과하면 추출효율이 떨어지는 문제가 있을 수 있으므로 상기 부피% 농도의 에탄올 수용액을 사용하는 것이 바람직하다.In the first step of the alcohol extract manufacturing process, the aqueous alcohol solution may use an aqueous solution of a lower alcohol having 1 to 4 carbon atoms, preferably an aqueous ethanol solution, and more preferably an aqueous ethanol solution having a concentration of 65 to 80% by volume. there is. When using an aqueous ethanol solution, if the concentration of the aqueous ethanol solution is less than 65% by volume, the content of the physiologically active active ingredient in the extract may be low, and if the concentration exceeds 80% by volume, there may be a problem with a drop in extraction efficiency. It is preferable to use
상기 미성숙 딸기 과육 알코올 추출물 제조공정에 있어서, 상기 3단계는 1 ~ 3회 반복 수행할 수 있다. 그리고, 4단계의 진공감압농축은 당업계에서 사용하는 일반적인 진공감압농축법으로 수행할 수 있으며, 그 방법을 특별하게 한정하지 않는다. 또한, 상기 동결건조 역시 당업계에서 사용하는 일반적인 동결건조법으로 수행할 수 있다.In the manufacturing process of the immature strawberry pulp alcohol extract, the above three steps may be repeated 1 to 3 times. In addition, the vacuum concentration in step 4 may be performed by a general vacuum concentration method used in the art, and the method is not particularly limited. In addition, the freeze-drying may also be performed by a general freeze-drying method used in the art.
이러한 방법으로 제조된 본 발명의 딸기 미성숙과열수 추출물 및/또는 알코올 추출물은 항산화 활성 효과가 우수하며, 항염증 효과가 우수하다.The unripe superheated strawberry extract and/or alcohol extract of the present invention prepared in this way has excellent antioxidant activity and anti-inflammatory effect.
본 발명의 미성숙 딸기 과육 추출물은 총 폴리페놀 함량이 1.50 ~ 3.50 mg tanninc acid/g일 수 있으며, 바람직하게는 1.70 ~ 3.50 mg tanninc acid/g, 더욱 바람직하게는 1.80 ~ 3.20 mg tanninc acid/g일 수 있다.The immature strawberry pulp extract of the present invention may have a total polyphenol content of 1.50 to 3.50 mg tanninc acid/g, preferably 1.70 to 3.50 mg tanninc acid/g, and more preferably 1.80 to 3.20 mg tanninc acid/g. can
또한, 본 발명의 미성숙 딸기 과육 추출물은 DPPH 라디칼 소거능 측정시, 추출물의 농도가 1000 ppm(μg/ml)일 때, 하기 식 1에 의거한 DPPH 라디칼 소거능은 88% 이상, 바람직하게는 89.00% 이상, 더욱 바람직하게는 90.0 ~ 95.00%일 수 있다.In addition, when the DPPH radical scavenging activity of the immature strawberry pulp extract of the present invention is measured, when the concentration of the extract is 1000 ppm (μg/ml), the DPPH radical scavenging activity according to the following
[식 1][Equation 1]
DPPH 라디칼 소거능(%) = {1-(샘플 흡광도/음성대조군 흡광도)}×100%DPPH radical scavenging ability (%) = {1-(sample absorbance/negative control absorbance)}×100%
식 1의 샘플 흡광도는 미성숙 딸기 과육 추출물 0.5 ml에 DPPH를 60 μM 로 포함하는 에탄올 용액 3 ml을 혼합하여 암실에서 15분간 반응한 다음 분광광도계를 사용하여 517 nm에서 측정한 것이고, 음성대조군 흡광도는 증류수 0.5 ml에 DPPH를 60 μM 로 포함하는 에탄올 용액 3 ml을 혼합하여 암실에서 15분간 반응한 다음 분광광도계를 사용하여 517 nm에서 측정한 것이다.The absorbance of the sample in
또한, 본 발명의 미성숙 딸기 과육 추출물은 ABTS 라디칼 소거능 측정시, 추출물의 농도가 1000 ppm(μg/ml)일 때, 하기 식 2에 의거한 ABTS 라디칼 소거능은 90% 이상, 바람직하게는 92% 이상, 더욱 바람직하게는 92.0 ~ 98.0%일 수 있다.In addition, when measuring the ABTS radical scavenging activity of the immature strawberry pulp extract of the present invention, when the concentration of the extract is 1000 ppm (μg/ml), the ABTS radical scavenging activity based on the following
[식 2][Equation 2]
ABTS 라디칼 소거능(%) = {1-(샘플 흡광도/음성대조군 흡광도)}×100%ABTS radical scavenging ability (%) = {1-(sample absorbance/negative control absorbance)}×100%
식 2의 샘플 흡광도는 미성숙 딸기 과육 추출물 150 μl와 ABTS 용액 3 ml를 혼합하여 30초간 보텍스(vortex)하 후 3분 간 25℃에서 반응시키고 734 nm에서 흡광도를 측정한 것이고, 음성대조군 흡광도는 증류수 150 μl와 ABTS 용액 3 ml를 혼합하여 30초간 보텍스(vortex)하 후 3분 간 25℃에서 반응시키고 734 nm에서 흡광도를 측정한 것이다.The absorbance of the sample in
또한, 본 발명의 미성숙 딸기 과육 추출물은 NO 저해능 측정시, 추출물 농도가 500 ppm(μg/ml)일 때, 하기 식 3에 의거하여 측정한 NO 저해능이 20% 이상, 바람직하게는 일 수 있으며, 바람직하게는 23.0 ~ 32.0%일 수 있다.In addition, the immature strawberry pulp extract of the present invention, when measuring the NO inhibitory ability, when the extract concentration is 500 ppm (μg / ml), the NO inhibitory ability measured according to the following formula 3 is 20% or more, preferably , Preferably it may be 23.0 ~ 32.0%.
[식 3][Equation 3]
NO 저해능(%) = 대조군의 NO 측정 레벨(%)- 추출물의 NO 측정 레벨(%)NO inhibition ability (%) = measured NO level of control (%) - measured NO level of extract (%)
상기 식 3의 NO 저해능은 RAW 264.7 세포에 LPS(Lipopolysaccharide)를 10 μg/ml 처리한 다음 2시간 뒤에 미성숙 딸기 과육 추출물을 일정 농도로 처리한 후, 18시간 동안 배양한 후, 배양액 내의 NO양을 측정한 것이며, 상기 대조군의 NO 측정 레벨은 100%이며, 추출물의 NO 측정 레벨은 측정된 NO양을 대조군 기준으로 %로 환산시킨 값이다.The NO inhibition ability of Equation 3 was determined by treating RAW 264.7 cells with 10 μg/ml of LPS (Lipopolysaccharide), then treating immature strawberry pulp extract at a
또한, 본 발명의 미성숙 딸기 과육 추출물은 추출물 농도가 500 ppm(μg/ml)일 때, 하기 식 4에 의거하여 측정한 iNOS 발현 저해능이 80% 이상일 수 있으며, 바람직하게는 85.0 ~ 95.0%, 더욱 바람직하게는 88.0 ~ 95.0%일 수 있다.In addition, when the immature strawberry pulp extract of the present invention has an extract concentration of 500 ppm (μg/ml), the iNOS expression inhibition ability measured according to Equation 4 below may be 80% or more, preferably 85.0 to 95.0%, and more Preferably it may be 88.0 to 95.0%.
[식 4][Equation 4]
iNOS 발현 저해능(%) = 음성대조군의 iNOS 발현율(%)- 추출물의 iNOS 발현율(%)iNOS expression inhibition ability (%) = iNOS expression rate of negative control group (%) - iNOS expression rate of extract (%)
상기 식 4에서 음성대조군은 자극제인 LPS를 단독으로 처리한 뒤 측정한 iNOS 발현율이며, 추출물의 iNOS 발현율은 딸기꼭지 추출물로 처리한 뒤 측정한 iNOS 발현율이며, 발현율은 측정된 iNOS 발현량을 음성대조군 기준으로 %로 환산시킨 값이다.In Equation 4, the negative control group is the iNOS expression rate measured after treatment with the stimulant LPS alone, the iNOS expression rate of the extract is the iNOS expression rate measured after treatment with the strawberry stalk extract, and the expression rate is the negative control group It is a value converted to % as a standard.
또한, 본 발명의 미성숙 딸기 과육 추출물은 추출물 농도가 500 ppm(μg/ml)일 때, 하기 식 5에 의거하여 측정한 COX-2 발현 저해능이 30.0% 이상일 수 있으며, 바람직하게는 31.0 ~ 40.0%, 더욱 바람직하게는 32.0 ~ 38.0%일 수 있다.In addition, when the immature strawberry pulp extract of the present invention has an extract concentration of 500 ppm (μg/ml), the COX-2 expression inhibitory ability measured according to the following
[식 5][Equation 5]
COX-2 발현 저해능(%) = 대조군의 COX-2 발현율(%)- 추출물의 COX-2 발현율(%)COX-2 expression inhibition ability (%) = COX-2 expression rate of control (%) - COX-2 expression rate of extract (%)
상기 식 5에서 음성대조군은 자극제인 LPS를 단독으로 처리한 뒤 측정한 COX-2 발현율이며, 추출물의 iNOS 발현율은 딸기꼭지 추출물로 처리한 뒤 측정한 COX-2 발현율이며, 발현율은 측정된 COX-2 발현량을 음성대조군 기준으로 %로 환산시킨 값이다.In
본 발명의 미성숙 딸기 과육 추출물 유효성분으로 포함하는 조성물을 이용하여 과자, 음료수, 사탕, 캡슐, 영양제 등 다양한 식품으로 가공하여 건강기능식품 또는 이너뷰티 제품을 제공할 수 있다.Using the composition containing the immature strawberry pulp extract as an active ingredient of the present invention, it is possible to provide health functional foods or inner beauty products by processing various foods such as sweets, beverages, candies, capsules, and nutritional supplements.
또한, 피부용 화장품, 두피용 화장품, 헤어용 화장품 등 다양한 화장품의 화장료로도 사용할 수 있다.In addition, it can be used as a cosmetic for various cosmetics such as skin cosmetics, scalp cosmetics, and hair cosmetics.
이상에서 본 발명에 대하여 구현예를 중심으로 설명하였으나 이는 단지 예시일 뿐 본 발명의 구현예를 한정하는 것이 아니며, 본 발명의 실시예가 속하는 분야의 통상의 지식을 가진 자라면 본 발명의 본질적인 특성을 벗어나지 않는 범위에서 이상에 예시되지 않은 여러 가지의 변형과 응용이 가능함을 알 수 있을 것이다. 예를 들어, 본 발명의 구현예에 구체적으로 나타난 각 구성 요소는 변형하여 실시할 수 있는 것이다. 그리고 이러한 변형과 응용에 관계된 차이점들은 첨부된 청구 범위에서 규정하는 본 발명의 범위에 포함되는 것으로 해석되어야 할 것이다.In the above, the present invention has been described with a focus on embodiments, but this is only an example and does not limit the embodiments of the present invention, and those skilled in the art to which the embodiments of the present invention belong will appreciate the essential characteristics of the present invention. It will be appreciated that various modifications and applications not exemplified above are possible within a range that does not deviate. For example, each component specifically shown in the embodiment of the present invention can be modified and implemented. And differences related to these modifications and applications should be construed as being included in the scope of the present invention as defined in the appended claims.
[실시예][Example]
실시예 1 : 미성숙 딸기 과육 에탄올 추출물의 제조Example 1: Preparation of immature strawberry pulp ethanol extract
충청북도 청주시에서 2021년 5월까지 딸기의 완숙 과실을 모두 채취 후에 남은 미성숙과를 채취한 후, 꽃받침을 제거하여 미성숙 딸기 과육을 준비하였다.Immature strawberry pulp was prepared by removing the calyx after collecting all ripe fruits of strawberries by May 2021 in Cheongju, Chungcheongbuk-do.
다음으로, 이를 세척 및 열풍건조한 다음 파쇄하여 딸기 분말을 제조하였다.Next, it was washed and dried with hot air, and then crushed to prepare strawberry powder.
다음으로, 상기 딸기 분말을 70부피% 농도의 에탄올 수용액에 첨가하였다. 이때, 딸기 미성숙과분말과 에탄올 수용액의 혼합비는 1 : 10 중량비였다.Next, the strawberry powder was added to an aqueous ethanol solution having a concentration of 70% by volume. At this time, the mixing ratio of unripe strawberry powder and aqueous ethanol solution was 1:10 by weight.
다음으로, 25℃에서 24시간 동안 교반시켜준 후 부직포로 1차 여과하여 상등액과 침전물을 분리하였으며, 상기 여과 및 분리를 3회 반복하였다.Next, after stirring at 25 ° C. for 24 hours, the supernatant and the precipitate were separated by primary filtration with a non-woven fabric, and the filtration and separation were repeated three times.
이때, 여과 및 분리는 진공펌프와 여과지(Whatman No .5, No. 4, No .2)를 이용하여 여과하여 수행하였다.At this time, filtration and separation were performed by filtration using a vacuum pump and filter paper (Whatman No.5, No. 4, No.2).
다음으로, 침전물로부터 분리한 상등액을 로터리 진공 증류기(ratory vacuum진공감evaporator, EYEKA, Japan)을 사용하여 감압농축을 수행하여 농축물을 수득한 후, -20 ℃에서 동결건조 및 보관하여 미성숙 딸기 과육 에탄올 추출물을 수득하였다.Next, the supernatant separated from the precipitate was concentrated under reduced pressure using a rotary vacuum evaporator (EYEKA, Japan) to obtain a concentrate, and then freeze-dried and stored at -20 ° C to obtain immature strawberry pulp. An ethanol extract was obtained.
실험예 1 : 총 폴리페놀 함량 측정Experimental Example 1: Total polyphenol content measurement
상기 실시예 1의 미성숙 딸기 과육 알코올 추출물의 총 폴리페놀 함량을 Folin-Denis법을 하기와 같이 변형하여 측정하였고, 그 결과를 하기 표 1 및 도 1에 나타내었다.The total polyphenol content of the immature strawberry pulp alcohol extract of Example 1 was measured by modifying the Folin-Denis method as follows, and the results are shown in Table 1 and FIG. 1 below.
측정 방법은 추출물을 증류수에 희석한 다음 2ml과 50% Folin-ciocalteu reagent 2 ml를 혼합한 후 실온에 3분간 방치하였다. 그 후 10% Ca2CO3 2 ml를 가하여 혼합 후 상온에서 1시간 동안 방치하였다가 흡광도 700 nm에서 측정하였다.The measurement method was to dilute the extract in distilled water, mix 2ml and 50% Folin-ciocalteu reagent, and then leave it at room temperature for 3 minutes. Thereafter, 2 ml of 10% Ca 2 CO 3 was added, mixed, and allowed to stand at room temperature for 1 hour, and the absorbance was measured at 700 nm.
일반적으로 페놀성 성분들의 함량 수치와 자유라디칼과 높은 상관관계를 가지고 있으며, 페놀 함량이 증가할수록 항산화 등 생리활성 효과에 매우 좋은 효과를 나타내며, 각 시료의 폴리페놀 함량을 측정한 후 시료 g당 함유하고 있는 양을 나타내었다.In general, there is a high correlation between the content of phenolic components and free radicals, and as the phenol content increases, it shows a very good effect on physiological activities such as antioxidant. After measuring the polyphenol content of each sample, the content per gram of sample indicated the amount of
상기 표 1에서 보는 바와 같이 미성숙 딸기 과육 에탄올 추출물은 1.78±0.94 mg/g의 높은 폴리페놀 함량을 나타내었다.As shown in Table 1, the ethanol extract of immature strawberry pulp showed a high polyphenol content of 1.78±0.94 mg/g.
실험예 2 : 항산화 효과 측정Experimental Example 2: Measurement of antioxidant effect
상기 실시예 1의 미성숙 딸기 과육 알코올 추출물의 항산화 효과 측정으로서, 전자공여능 및 ABTS 라디칼 소거능 측정을 하기와 같이 수행하였다.As the antioxidant effect of the immature strawberry pulp alcohol extract of Example 1, electron donating ability and ABTS radical scavenging activity were measured as follows.
(1) 전자공여능 측정(1) Measurement of electron donating ability
전자공여능으로서 DPPH (1,1-diphenyl-2-picrylhydrazyl) 라디칼 소거 활성 실험은 Blois MS의 방법을 변형하여 시행하였으며, 미성숙 딸기 과육 추출물(시료) 0.5 ml에 60 μM DPPH (in EtOH) 3 ml을 혼합하여 암실에서 15분간 반응한 다음 분광광도계를 사용하여 517 nm에서 측정하였다. 그리고, DPPH 소거능은 하기 식 1에 의거하여 계산하였으며, 그 결과를 하기 표 2 및 도 1에 나타내었다.DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging activity test as an electron donating ability was performed by modifying the Blois MS method, and 3 ml of 60 μM DPPH (in EtOH) was added to 0.5 ml of immature strawberry pulp extract (sample). After mixing and reacting in a dark room for 15 minutes, measurement was performed at 517 nm using a spectrophotometer. In addition, the DPPH scavenging ability was calculated based on
이때, 음성대조군은 증류수를 사용하였고, 양성대조군으로는 아스코르빈산(Vit.C)를 사용하였다.At this time, distilled water was used as the negative control group, and ascorbic acid (Vit.C) was used as the positive control group.
[식 1][Equation 1]
DPPH 라디칼 소거능(%) = {1-(샘플 흡광도/음성대조군 흡광도}}×100%DPPH radical scavenging ability (%) = {1-(sample absorbance/negative control absorbance}}×100%
식 1의 샘플 흡광도는 미성숙 딸기 과육 추출물 0.5 ml에 DPPH를 60 μM 로 포함하는 에탄올 용액 3 ml을 혼합하여 암실에서 15분간 반응한 다음 분광광도계를 사용하여 517 nm에서 측정한 것이고, 음성대조군 흡광도는 증류수 0.5 ml에 DPPH를 60 μM 로 포함하는 에탄올 용액 3 ml을 혼합하여 암실에서 15분간 반응한 다음 분광광도계를 사용하여 517 nm에서 측정한 것이다.The absorbance of the sample in
표 2의 측정 결과를 살펴보면, DPPH 라디칼 소거능이 실시예 1은 500ppm 이상부터 90% 이상을 보였다. 이를 통해서, 본 발명의 미성숙 딸기 과육 에탄올 추출물이 우수한 DPPH 라디칼 소거능을 가지는 것을 확인할 수 있었다.Looking at the measurement results of Table 2, the DPPH radical scavenging ability of Example 1 showed more than 90% from 500 ppm or more. Through this, it was confirmed that the immature strawberry pulp ethanol extract of the present invention had excellent DPPH radical scavenging activity.
(2) ABTS 라디칼 소거능 측정(2) Measurement of ABTS radical scavenging ability
ABTS 라디칼 소거능은 Nicoletta의 방법3)을 따라 측정하였다. 7 mM ABTS 5 ml와 140 mM, K2S2O8 88 μl를 섞어 암실에 14 ~ 16시간 반응시켰다. 이를 에탄올(absolute ethanol)과 1:88 비율로 섞어 734 nm에서 흡광도 값이 0.7±0.002가 되도록 조절한 ABTS 용액을 제조하였다.ABTS radical scavenging ability was measured according to Nicoletta's method 3). 5 ml of 7 mM ABTS and 88 μl of 140 mM K 2 S 2 O 8 were mixed and reacted in the dark for 14 to 16 hours. This was mixed with ethanol (absolute ethanol) in a ratio of 1:88 to prepare an ABTS solution having an absorbance value of 0.7±0.002 at 734 nm.
미성숙 딸기 과육 추출물(시료) 150 μl와 ABTS 용액 3 ml를 혼합하여 30초간 보텍스(vortex)한 후 2.3분 간 상온에서 반응시키고 734 nm에서 흡광도를 측정하였다. 그리고, ABTS 라디칼 소거능은 하기 식 2에 의거하여 계산하였으며, 그 결과를 하기 표 3 및 도 2에 나타내었다.150 μl of immature strawberry pulp extract (sample) and 3 ml of ABTS solution were mixed, vortexed for 30 seconds, reacted at room temperature for 2.3 minutes, and absorbance was measured at 734 nm. In addition, the ABTS radical scavenging ability was calculated based on
이때, 음성대조군은 증류수를 사용하였고, 양성대조군으로는 아스코르빈산(Vit.C)를 사용하였다.At this time, distilled water was used as the negative control group, and ascorbic acid (Vit.C) was used as the positive control group.
[식 2][Equation 2]
ABTS 라디칼 소거능(%) = {1-(샘플 흡광도/음성대조군 흡광도}}×100%ABTS radical scavenging ability (%) = {1-(sample absorbance/negative control absorbance}}×100%
식 2의 샘플 흡광도는 미성숙 딸기 과육 추출물 150 μl와 ABTS 용액 3 ml를 혼합하여 30초간 보텍스(vortex)하 후 3분 간 25℃에서 반응시키고 734 nm에서 흡광도를 측정한 것이고, 음성대조군 흡광도는 증류수 150 μl와 ABTS 용액 3 ml를 혼합하여 30초간 보텍스(vortex)하 후 3분 간 25℃에서 반응시키고 734 nm에서 흡광도를 측정한 것이다.The absorbance of the sample in
표 3의 측정 결과를 살펴보면, ABTS 라디칼 소거능이 실시예 1은 500ppm 이상부터 90% 이상을 보였으며, 1,000 μg/ml 농도에서 더 이상의 ABTS 라디칼 소거능 증대 효과는 없었다. 이를 통해서, 본 발명의 미성숙 딸기 과육 에탄올 추출물이 우수한 ABTS 라디칼 소거능을 가지는 것을 확인할 수 있었다.Looking at the measurement results of Table 3, the ABTS radical scavenging ability of Example 1 was 90% or more from 500 ppm or more, and there was no further effect of increasing the ABTS radical scavenging ability at a concentration of 1,000 μg / ml. Through this, it was confirmed that the immature strawberry pulp ethanol extract of the present invention had excellent ABTS radical scavenging activity.
실험예 3 : 세포 독성 측정Experimental Example 3: Measurement of cytotoxicity
미성숙 딸기 과육 추출물이 세포에 노출되었을 때 세포에 미치는 독성을 확인하기 위하여 MTT assay를 진행하였다.MTT assay was performed to confirm the toxicity of immature strawberry pulp extract to cells when exposed to cells.
먼저 96 웰 세포배양기에 1×10⁴ cells/well 되도록 RAW264.7 세포를 분주한 후 24시간 뒤에 각 농도에 맞도록 DMSO(dimethyl sulfoxide)에 녹인 샘플을 첨가하였다. 24시간 뒤에 배지를 제거한 후 MTT(2-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-2H-tetrazolium bromide) 시약 (in PBS 2.5 mg/ml) well에 40 μl씩 가하고 세포배양기(incubator)에 4시간 반응 후 다시 상층액을 제거하였다.First, after dispensing RAW264.7 cells to 1 × 10⁴ cells/well in a 96-well cell culture medium, samples dissolved in DMSO (dimethyl sulfoxide) were added to suit each concentration after 24 hours. After removing the medium after 24 hours, 40 μl of MTT (2-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-2H-tetrazolium bromide) reagent (in PBS 2.5 mg/ml) was added to the well, and the cell culture medium ( After reacting for 4 hours in the incubator), the supernatant was removed again.
다음으로, DMSO를 100 μl씩 분주하여 완전히 녹인 후, 분광광도계를 이용하여 흡광도 540 nm에서 측정하였고, 그 결과를 도 3에 나타내었다.Next, after dispensing 100 μl of DMSO and completely dissolving it, the absorbance was measured at 540 nm using a spectrophotometer, and the results are shown in FIG. 3 .
RAW264.7의 세포 독성 측정 결과, 실시예 1(에탄올 추출물)은 500 μg/ml 농도에서 90% 이상의 높은 세포 생존율이 나타나는 것을 확인하였고, 1000 μg/ml 에서는 상대적으로 세포 생존율이 낮아졌고, 이는 약한 세포독성 있음을 나타내는 것이다.As a result of measuring the cytotoxicity of RAW264.7, Example 1 (ethanol extract) confirmed that a high cell viability of 90% or more was exhibited at a concentration of 500 μg/ml, and the cell viability was relatively low at 1000 μg/ml, which was weak. indicates cytotoxicity.
이러한 결과를 바탕으로, 세포 생존율이 감소가 없는 범위에서 가장 높은 농도인 500 μg/ml 농도인 추출물을 사용하여, 이하에서 NO, iNOS 및 COX-2의 단백질 발현 측정 시험을 진행하였다.Based on these results, the protein expression measurement test of NO, iNOS, and COX-2 was conducted below using the extract having the highest concentration of 500 μg/ml in the range where cell viability is not reduced.
실험예 4 : 항염증 측정Experimental Example 4: Anti-inflammatory measurement
(1) 일산화질소(NO) 저해능 측정(1) Measurement of nitric oxide (NO) inhibition
염증반응의 대표적인 인자인 NO의 생성 억제하는지 확인하기 위해 RAW 264.7 세포에 LPS(Lipopolysaccharide)를 10 μg/ml 처리한 다음 2시간 뒤에 추출물을 각 농도별로 처리하였다. 18시간 동안 배양 후 배양액 내의 NO양을 측정하였고, 그 결과를 도 4에 나타내었다.In order to determine whether production of NO, a representative factor of the inflammatory response, was inhibited, RAW 264.7 cells were treated with 10 μg/ml of LPS (Lipopolysaccharide), and then the extract was treated at each concentration after 2 hours. After culturing for 18 hours, the amount of NO in the culture medium was measured, and the results are shown in FIG. 4 .
NO 저해 활성 측정은, RAW 264.7 세포의 상청액(supernatant)에서의 NO 양을 아질산염(nitrite)과 질산염(nitrate)로서 측정하였다. 아질산염에 대한 질산염으로 환원된 후의 안전한 형태인 그리스 시약(griess reagent)을 사용하였으며, 96웰 세포배양기 1×10⁴cells/well로 분주된 RAW264.7 세포의 컨플루언스(confluence)가 80%일 때, PBS(phosphate buffered saline)로 2번 수세(washing)한 후에 무혈청 배지를 사용하여 18시간 이상 배양시킨 후에 시료를 농도별로 처리하여 1시간 동안 배양한 후 LPS(lipopolysaccharide) 1 μg/ml 처리하고 24 시간 동안 배양하였다. 배양액의 상층액을 취하여 그리스 시약과 반응시킨 후 ELISA 리더기(reader)로 540 nm에서 흡광도를 측정하여 NO 생성율을 백분율로 표시하였다.NO inhibitory activity measurement, the amount of NO in the supernatant (supernatant) of RAW 264.7 cells was measured as nitrite (nitrite) and nitrate (nitrate). A grease reagent, which is a safe form after reduction with nitrate for nitrite, was used, and when the confluence of RAW264.7 cells dispensed at 1 × 10⁴cells/well in a 96-well cell culture medium was 80%, After washing twice with PBS (phosphate buffered saline) and culturing for more than 18 hours using a serum-free medium, the samples were treated by concentration and cultured for 1 hour, treated with 1 μg/ml of LPS (lipopolysaccharide), and then cultured for 24 hours. incubated for hours. The supernatant of the culture was reacted with a grease reagent, and then the absorbance was measured at 540 nm using an ELISA reader, and the NO production rate was expressed as a percentage.
LPS 단독 처리군과 LPS 무처리군에서의 차이가 나타나는 것을 확인하였으며, LPS와 농도별로 추출물을 처리하였을 때, 실시예 1(에탄올 추출물)은 농도 의존적으로 NO 생성량이 감소하는 것을 확인하였다. 이때, NO 저해능은 하기 식 3에 의거하여 측정하였다.It was confirmed that there was a difference between the LPS-only treatment group and the LPS-untreated group, and when the extract was treated by LPS and concentration, Example 1 (ethanol extract) confirmed that NO production decreased in a concentration-dependent manner. At this time, the NO inhibition ability was measured based on Equation 3 below.
500 μg/ml 농도에서 실시예 1은 25.01%의 저해 효과를 확인하였다.At a concentration of 500 μg/ml, Example 1 confirmed an inhibitory effect of 25.01%.
[식 3][Equation 3]
NO 저해능(%) = 대조군의 NO 측정 레벨(%) - 추출물의 NO 측정 레벨(%)NO inhibition ability (%) = measured NO level of control (%) - measured NO level of extract (%)
식 3의 NO 저해능은 RAW 264.7 세포에 LPS를 10 μg/ml 처리한 다음 2시간 뒤에 미성숙 딸기 과육 추출물을 일정 농도로 처리한 후, 18시간 동안 배양한 후, 배양액 내의 NO양을 측정한 것이며, 상기 대조군의 NO 측정 레벨은 100%이며, 추출물의 NO 측정 레벨은 측정된 NO양을 대조군 기준으로 %로 환산시킨 값이다.The NO inhibition ability of Equation 3 was obtained by treating RAW 264.7 cells with 10 μg/ml of LPS, then treating immature strawberry pulp extract at a
(2) 웨스턴 블랏(western blot)을 통한 iNOS, COX-2발현 저해능 측정(2) Measurement of iNOS and COX-2 expression inhibition by western blot
염증의 매개 인자인 iNOS, COX-2의 단백질 발현량에 미치는 실시예 1(에탄올추출물)의 항염증 효과를 확인하였고, 그 결과를 도 5의 A(iNOS 발현) 및 B(COX-2 발현)에 나타내었다.The anti-inflammatory effect of Example 1 (ethanol extract) on the protein expression levels of iNOS and COX-2, which are mediators of inflammation, was confirmed, and the results are shown in FIG. 5 A (iNOS expression) and B (COX-2 expression) shown in
단백질 발현량 측정 방법은 RAW264.7 세포를 10% FBS(fetal bovine serum)를 포함한 DMEM(Dulbecco's modified Eagle's medium)에 현탁시킨 후, 6 웰 세포배양기에 2×105 cells/well의 세포수가 되도록 3 ml씩 분주하여 37℃, 5% CO2 배양기에서 24시간 배양하였다. 다음으로, 새로운 DMEM 배지로 교환한 후 2시간 동안 자극제인 LPS를 처리하여 배양한 후 딸기꼭지 추출물을 농도별로 세포에 처리하여 배양하였다. 24시간 후 단백질 발현을 측정하기 위하여 배지를 제거하고 차가운 PBS로 세척한 후 세포 용해물(cell lysates)는 RIPA 버퍼(buffer)에 Protease&Phosphatase Single-Use inhibitor Cocktail 100X를 첨가하여 단백질을 추출하였다. 단백질을 정량(BCA protein kit)하여, 10% SDS-PAGE에 전기영동한 후, 멤브레인(membrane)으로 이주(transfer)하여 5% 탈지유(5% skim milk in TBST)에 2시간 동안 블로킹(blocking)하였다. 1차 항체를 희석(3% skim milk in TBST)하여 4℃에서 오버나이트(overnight)한 다음, TBST(Tris buffered saline with tween 20)로 3회 세척하였다. 2차 항체는 실온에서 2시간 동안 배양하여 측정하였다.To measure the protein expression level, RAW264.7 cells were suspended in DMEM (Dulbecco's modified Eagle's medium) containing 10% FBS (fetal bovine serum), and then cultured in a 6-well cell culture medium so that the cell number was 2×10 5 cells/well. Divided by ml, and cultured for 24 hours in a 37°C, 5% CO 2 incubator. Next, the cells were cultured by treating the stimulant, LPS, for 2 hours after exchanging with a new DMEM medium, and then treating the cells with strawberry stem extract at each concentration and cultured. After 24 hours, to measure protein expression, the medium was removed, washed with cold PBS, and protein was extracted from the cell lysates by adding Protease & Phosphatase Single-Use inhibitor Cocktail 100X to RIPA buffer. Protein was quantified (BCA protein kit), electrophoresed on 10% SDS-PAGE, transferred to a membrane, and blocked in 5% skim milk in TBST for 2 hours did The primary antibody was diluted (3% skim milk in TBST), overnight at 4°C, and washed three times with TBST (Tris buffered saline with tween 20). Secondary antibodies were measured by incubation at room temperature for 2 hours.
iNOS 및 COX-2의 단백질 발현은 ECL(enhanced chemiluminescence) 용액(Amersham, Pittsburgh, PA, USA)을 이용하여 확인하였다. 내부통제9Internal control)로써 1:1000으로 희석한 베타-엑틴(β-actin, Santa Cruz Biotechnology, Santa Cruz, California, USA)을 사용하였다.The protein expression of iNOS and COX-2 was confirmed using an enhanced chemiluminescence (ECL) solution (Amersham, Pittsburgh, PA, USA). 1:1000 diluted beta-actin (Santa Cruz Biotechnology, Santa Cruz, California, USA) was used as an internal control (9).
음성대조군은(Con) 미성숙 딸기 과육 에탄올 추출물 대신 자극제인 LPS를 단독으로 처리한 것이고, 정상군은 자극제인 LPS와 미성숙 딸기 과육 추출물을 처리하지 않은 것이다.The negative control group (Con) was treated with stimulant LPS alone instead of immature strawberry pulp ethanol extract, and the normal group was not treated with stimulant LPS and immature strawberry pulp extract.
그리고, iNOS 발현 저해능은 하기 식 4에 의거하여 계산하였고, COX-2 발현 저해능은 식 5에 의거하여 계산하였다.In addition, the ability to inhibit iNOS expression was calculated based on Equation 4 below, and the ability to inhibit COX-2 expression was calculated based on
[식 4][Equation 4]
iNOS 발현 저해능(%) = 음성대조군의 iNOS 발현율(%)- 추출물의 iNOS 발현율(%)iNOS expression inhibition ability (%) = iNOS expression rate of negative control group (%) - iNOS expression rate of extract (%)
상기 식 4의 iNOS 발현 저해능은 iNOS 발현량을 측정한 것이며, 상기 음성대조군의 iNOS 발현율은 100%이며, 추출물의 iNOS 발현율은 측정된 iNOS 발현량을 대조군 기준으로 %로 환산시킨 값이다.The ability to inhibit iNOS expression in Equation 4 is obtained by measuring the iNOS expression level, the iNOS expression level of the negative control group is 100%, and the iNOS expression level of the extract is the value obtained by converting the measured iNOS expression level to % based on the control group.
[식 5][Equation 5]
COX-2 발현 저해능(%) = 음성대조군의 COX-2 발현율(%)- 추출물의 COX-2 발현율(%)COX-2 expression inhibition ability (%) = COX-2 expression rate of negative control group (%) - COX-2 expression rate of extract (%)
상기 식 5의 COX-2 발현 저해능은 COX-2 발현량을 측정한 것이며, 상기 대조군의 COX-2 발현율은 100%이며, 추출물의 COX-2 발현율은 측정된 COX-2 발현량을 대조군 기준으로 %로 환산시킨 값이다.The ability to inhibit COX-2 expression in
도 5를 살펴보면, RAW 264.7 세포에 추출물을 10, 50, 100, 500 μg/ml 농도로 처리하고 각 단백질의 발현량을 측정한 결과 미성숙 딸기 과육의 70 부피% 에탄올 추출물은 500 μg/ml 농도에서 iNOS, COX-2의 단백질 발현은 각각 89.65%, 33.56% 저해하는 것을 확인하였다.Referring to FIG. 5, RAW 264.7 cells were treated with extracts at concentrations of 10, 50, 100, and 500 μg/ml, and the expression level of each protein was measured. It was confirmed that the protein expression of iNOS and COX-2 was inhibited by 89.65% and 33.56%, respectively.
이를 통해서, 본 발명의 미성숙 딸기 과육 추출물이 항염증성이 우수함을 확인할 수 있었다.Through this, it was confirmed that the immature strawberry pulp extract of the present invention had excellent anti-inflammatory properties.
상기 실시예 및 실험예를 통하여, 본 발명의 미성숙 딸기 알코올 추출물이 우수한 항산화 및 항염증 효과가 있는 것을 확인할 수 있었으며, 이러한 본 발명의 추출물을 다양한 건강기능식품 소재 및/또는 화장료로 적용하기 적합함을 확인할 수 있었다.Through the above examples and experimental examples, it was confirmed that the immature strawberry alcohol extract of the present invention has excellent antioxidant and anti-inflammatory effects, and the extract of the present invention is suitable for application to various health functional food materials and / or cosmetics was able to confirm
본 발명의 단순한 변형이나 변경은 이 분야의 통상의 지식을 가진 자에 의해서 용이하게 실시될 수 있으며, 이러한 변형이나 변경은 모두 본 발명의 영역에 포함되는 것으로 볼 수 있다.Simple modifications or changes of the present invention can be easily performed by those skilled in the art, and all such modifications or changes can be considered to be included in the scope of the present invention.
Claims (10)
미성숙 딸기 과육 추출물은 65 ~ 80 부피% 농도의 에탄올 수용액 추출물이고,
미성숙 딸기 과육 추출물은, 총 폴리페놀 함량이 1.50 ~ 3.50 mg tanninc acid/g이고,
미성숙 딸기 과육 추출물 농도가 1000 ppm일 때, 하기 식 1에 의거하여 측정한 DPPH 라디칼 소거능이 90.0 ~ 95.00%이며, 하기 식 2에 의거하여 측정한 ABTS 라디칼 소거능이 92.0 ~ 98.0%이고,
미성숙 딸기 과육 추출물은 추출물 농도가 500 ppm일 때, 하기 식 3에 의거하여 측정한 NO 저해능이 23.0 ~ 32.0%이며, 하기 식 4에 의거하여 측정한 iNOS 발현 저해능이 85.0 ~ 95.0%이고, 하기 식 5에 의거하여 측정한 COX-2 발현 저해능이 31.0 ~ 40.0%인 것을 특징으로 하는 항산화 및 항염증성 조성물;
[식 1]
DPPH 라디칼 소거능(%) = {1-(샘플 흡광도/음성대조군 흡광도)}×100%
식 1의 샘플 흡광도는 미성숙 딸기 과육 추출물 0.5 ml에 DPPH를 60 μM 로 포함하는 에탄올 용액 3 ml을 혼합하여 암실에서 15분간 반응한 다음 분광광도계를 사용하여 517 nm에서 측정한 것이고, 음성대조군 흡광도는 증류수 0.5 ml에 DPPH를 60 μM 로 포함하는 에탄올 용액 3 ml을 혼합하여 암실에서 15분간 반응한 다음 분광광도계를 사용하여 517 nm에서 측정한 것이다.
[식 2]
ABTS 라디칼 소거능(%) = {1-(샘플 흡광도/음성대조군 흡광도)}×100%
식 2의 샘플 흡광도는 미성숙 딸기 과육 추출물 150 μl와 ABTS 용액 3 ml를 혼합하여 30초간 보텍스(vortex)하 후 3분 간 25℃에서 반응시키고 734 nm에서 흡광도를 측정한 것이고, 음성대조군 흡광도는 증류수 150 μl와 ABTS 용액 3 ml를 혼합하여 30초간 보텍스(vortex)하 후 3분 간 25℃에서 반응시키고 734 nm에서 흡광도를 측정한 것이다.
[식 3]
NO 저해능(%) = 대조군의 NO 측정 레벨(%)- 추출물의 NO 측정 레벨(%)
식 3의 NO 저해능은 RAW 264.7 세포에 LPS(Lipopolysaccharide)를 10 μg/ml 처리한 다음 2시간 뒤에 미성숙 딸기 과육 추출물을 일정 농도로 처리한 후, 18시간 동안 배양한 후, 배양액 내의 NO양을 측정한 것이며, 상기 대조군의 NO 측정 레벨은 100%이며, 추출물의 NO 측정 레벨은 측정된 NO양을 대조군 기준으로 %로 환산시킨 값이다.
[식 4]
iNOS 발현 저해능(%) = 음성대조군의 iNOS 발현율(%)- 추출물의 iNOS 발현율(%)
상기 식 4에서 음성대조군은 자극제인 LPS를 단독으로 처리한 뒤 측정한 iNOS 발현율이며, 추출물의 iNOS 발현율은 딸기꼭지 추출물로 처리한 뒤 측정한 iNOS 발현율이며, 발현율은 측정된 iNOS 발현량을 음성대조군 기준으로 %로 환산시킨 값이다.
[식 5]
COX-2 발현 저해능(%) = 음성대조군의 COX-2 발현율(%)- 추출물의 COX-2 발현율(%)
상기 식 5에서 음성대조군은 자극제인 LPS를 단독으로 처리한 뒤 측정한 COX-2 발현율이며, 추출물의 iNOS 발현율은 딸기꼭지 추출물로 처리한 뒤 측정한 COX-2 발현율이며, 발현율은 측정된 COX-2 발현량을 음성대조군 기준으로 %로 환산시킨 값이다.Contains immature strawberry pulp extract as an active ingredient,
The immature strawberry pulp extract is an ethanol aqueous solution extract with a concentration of 65 to 80% by volume,
The immature strawberry pulp extract had a total polyphenol content of 1.50 to 3.50 mg tanninc acid/g,
When the concentration of immature strawberry pulp extract was 1000 ppm, the DPPH radical scavenging activity measured according to the following formula 1 was 90.0 to 95.00%, and the ABTS radical scavenging activity measured according to the following formula 2 was 92.0 to 98.0%,
When the immature strawberry pulp extract had an extract concentration of 500 ppm, the NO inhibition ability measured according to the following formula 3 was 23.0 to 32.0%, and the iNOS expression inhibitory ability measured according to the following formula 4 was 85.0 to 95.0%, and the following formula An antioxidant and anti-inflammatory composition characterized in that the COX-2 expression inhibitory ability measured according to 5 is 31.0 to 40.0%;
[Equation 1]
DPPH radical scavenging ability (%) = {1-(sample absorbance/negative control absorbance)}×100%
The absorbance of the sample in Equation 1 was measured at 517 nm using a spectrophotometer after mixing 3 ml of an ethanol solution containing 60 μM DPPH with 0.5 ml of immature strawberry pulp extract and reacting in the dark for 15 minutes. 0.5 ml of distilled water was mixed with 3 ml of an ethanol solution containing 60 µM DPPH, reacted in the dark for 15 minutes, and then measured at 517 nm using a spectrophotometer.
[Equation 2]
ABTS radical scavenging ability (%) = {1-(sample absorbance/negative control absorbance)}×100%
The absorbance of the sample in Equation 2 was obtained by mixing 150 μl of immature strawberry pulp extract and 3 ml of ABTS solution, vortexing for 30 seconds, reacting at 25 ° C for 3 minutes, and measuring the absorbance at 734 nm. 150 μl and 3 ml of ABTS solution were mixed, vortexed for 30 seconds, reacted at 25° C. for 3 minutes, and absorbance was measured at 734 nm.
[Equation 3]
NO inhibition ability (%) = measured NO level of control (%) - measured NO level of extract (%)
The NO inhibition ability of Formula 3 was measured by treating RAW 264.7 cells with 10 μg/ml of LPS (Lipopolysaccharide), then treating immature strawberry pulp extract at a certain concentration 2 hours later, incubating for 18 hours, and then measuring the amount of NO in the culture medium. The NO measurement level of the control group is 100%, and the NO measurement level of the extract is a value obtained by converting the measured NO amount to % based on the control group.
[Equation 4]
iNOS expression inhibition ability (%) = iNOS expression rate of negative control group (%) - iNOS expression rate of extract (%)
In Equation 4, the negative control group is the iNOS expression rate measured after treatment with the stimulant LPS alone, the iNOS expression rate of the extract is the iNOS expression rate measured after treatment with the strawberry stalk extract, and the expression rate is the negative control group It is a value converted to % as a standard.
[Equation 5]
COX-2 expression inhibition ability (%) = COX-2 expression rate of negative control group (%) - COX-2 expression rate of extract (%)
In Equation 5, the negative control group is the COX-2 expression rate measured after treatment with the stimulant LPS alone, and the iNOS expression rate of the extract is the COX-2 expression rate measured after treatment with the strawberry stalk extract, and the expression rate is the measured COX-2 expression rate. 2 It is a value obtained by converting the expression level to % based on the negative control group.
상기 딸기 분말 및 65 ~ 80 부피% 농도의 에탄올 수용액을 1 : 10 중량비로 혼합한 후, 22 ~ 27℃에서 18 ~ 30시간 동안 교반을 수행하는 2단계;
2단계를 수행한 추출액을 여과하여 상등액과 침전물을 분리하는 3단계;
상등액을 진공감압농축을 수행하여 농축물을 수득한 후, 동결건조를 수행하여 미성숙 딸기 과육 추출물을 수득하는 4단계;를 포함하는 공정을 수행하며,
상기 3단계는 1 ~ 3회 반복 수행하고,
미성숙 딸기 과육 추출물은, 총 폴리페놀 함량이 1.50 ~ 3.50 mg tanninc acid/g이고,
미성숙 딸기 과육 추출물 농도가 1000 ppm일 때, 하기 식 1에 의거하여 측정한 DPPH 라디칼 소거능이 90.0 ~ 95.00%이며, 하기 식 2에 의거하여 측정한 ABTS 라디칼 소거능이 92.0 ~ 98.0%이고,
미성숙 딸기 과육 추출물은 추출물 농도가 500 ppm일 때, 하기 식 3에 의거하여 측정한 NO 저해능이 23.0 ~ 32.0%이며, 하기 식 4에 의거하여 측정한 iNOS 발현 저해능이 85.0 ~ 95.0%이고, 하기 식 5에 의거하여 측정한 COX-2 발현 저해능이 31.0 ~ 40.0%인 것을 특징으로 하는 미성숙 딸기 과육 추출물의 제조방법;
[식 1]
DPPH 라디칼 소거능(%) = {1-(샘플 흡광도/음성대조군 흡광도)}×100%
식 1의 샘플 흡광도는 미성숙 딸기 과육 추출물 0.5 ml에 DPPH를 60 μM 로 포함하는 에탄올 용액 3 ml을 혼합하여 암실에서 15분간 반응한 다음 분광광도계를 사용하여 517 nm에서 측정한 것이고, 음성대조군 흡광도는 증류수 0.5 ml에 DPPH를 60 μM 로 포함하는 에탄올 용액 3 ml을 혼합하여 암실에서 15분간 반응한 다음 분광광도계를 사용하여 517 nm에서 측정한 것이다.
[식 2]
ABTS 라디칼 소거능(%) = {1-(샘플 흡광도/음성대조군 흡광도)}×100%
식 2의 샘플 흡광도는 미성숙 딸기 과육 추출물 150 μl와 ABTS 용액 3 ml를 혼합하여 30초간 보텍스(vortex)하 후 3분 간 25℃에서 반응시키고 734 nm에서 흡광도를 측정한 것이고, 음성대조군 흡광도는 증류수 150 μl와 ABTS 용액 3 ml를 혼합하여 30초간 보텍스(vortex)하 후 3분 간 25℃에서 반응시키고 734 nm에서 흡광도를 측정한 것이다.
[식 3]
NO 저해능(%) = 대조군의 NO 측정 레벨(%)- 추출물의 NO 측정 레벨(%)
식 3의 NO 저해능은 RAW 264.7 세포에 LPS(Lipopolysaccharide)를 10 μg/ml 처리한 다음 2시간 뒤에 미성숙 딸기 과육 추출물을 일정 농도로 처리한 후, 18시간 동안 배양한 후, 배양액 내의 NO양을 측정한 것이며, 상기 대조군의 NO 측정 레벨은 100%이며, 추출물의 NO 측정 레벨은 측정된 NO양을 대조군 기준으로 %로 환산시킨 값이다.
[식 4]
iNOS 발현 저해능(%) = 음성대조군의 iNOS 발현율(%)- 추출물의 iNOS 발현율(%)
상기 식 4에서 음성대조군은 자극제인 LPS를 단독으로 처리한 뒤 측정한 iNOS 발현율이며, 추출물의 iNOS 발현율은 딸기꼭지 추출물로 처리한 뒤 측정한 iNOS 발현율이며, 발현율은 측정된 iNOS 발현량을 음성대조군 기준으로 %로 환산시킨 값이다.
[식 5]
COX-2 발현 저해능(%) = 음성대조군의 COX-2 발현율(%)- 추출물의 COX-2 발현율(%)
상기 식 5에서 음성대조군은 자극제인 LPS를 단독으로 처리한 뒤 측정한 COX-2 발현율이며, 추출물의 iNOS 발현율은 딸기꼭지 추출물로 처리한 뒤 측정한 COX-2 발현율이며, 발현율은 측정된 COX-2 발현량을 음성대조군 기준으로 %로 환산시킨 값이다.A first step of preparing strawberry powder by washing and drying immature strawberry pulp and then pulverizing it;
A second step of mixing the strawberry powder and 65 to 80% by volume aqueous ethanol solution at a weight ratio of 1:10, followed by stirring at 22 to 27° C. for 18 to 30 hours;
Step 3 of separating the supernatant and the precipitate by filtering the extract obtained in step 2;
Performing a process comprising: performing a vacuum concentration of the supernatant to obtain a concentrate, followed by freeze-drying to obtain an immature strawberry pulp extract;
The above 3 steps are repeated 1 to 3 times,
The immature strawberry pulp extract had a total polyphenol content of 1.50 to 3.50 mg tanninc acid/g,
When the concentration of immature strawberry pulp extract was 1000 ppm, the DPPH radical scavenging activity measured according to the following formula 1 was 90.0 to 95.00%, and the ABTS radical scavenging activity measured according to the following formula 2 was 92.0 to 98.0%,
When the immature strawberry pulp extract had an extract concentration of 500 ppm, the NO inhibition ability measured according to the following formula 3 was 23.0 to 32.0%, and the iNOS expression inhibitory ability measured according to the following formula 4 was 85.0 to 95.0%, and the following formula A method for producing an immature strawberry pulp extract, characterized in that the COX-2 expression inhibitory ability measured according to 5 is 31.0 to 40.0%;
[Equation 1]
DPPH radical scavenging ability (%) = {1-(sample absorbance/negative control absorbance)}×100%
The absorbance of the sample in Equation 1 was measured at 517 nm using a spectrophotometer after mixing 3 ml of an ethanol solution containing 60 μM DPPH with 0.5 ml of immature strawberry pulp extract and reacting in the dark for 15 minutes. 0.5 ml of distilled water was mixed with 3 ml of an ethanol solution containing 60 µM DPPH, reacted in the dark for 15 minutes, and then measured at 517 nm using a spectrophotometer.
[Equation 2]
ABTS radical scavenging ability (%) = {1-(sample absorbance/negative control absorbance)}×100%
The absorbance of the sample in Equation 2 was obtained by mixing 150 μl of immature strawberry pulp extract and 3 ml of ABTS solution, vortexing for 30 seconds, reacting at 25 ° C for 3 minutes, and measuring the absorbance at 734 nm. 150 μl and 3 ml of ABTS solution were mixed, vortexed for 30 seconds, reacted at 25° C. for 3 minutes, and absorbance was measured at 734 nm.
[Equation 3]
NO inhibition ability (%) = measured NO level of control (%) - measured NO level of extract (%)
The NO inhibition ability of Formula 3 was measured by treating RAW 264.7 cells with 10 μg/ml of LPS (Lipopolysaccharide), then treating immature strawberry pulp extract at a certain concentration 2 hours later, incubating for 18 hours, and then measuring the amount of NO in the culture medium. The NO measurement level of the control group is 100%, and the NO measurement level of the extract is a value obtained by converting the measured NO amount to % based on the control group.
[Equation 4]
iNOS expression inhibition ability (%) = iNOS expression rate of negative control group (%) - iNOS expression rate of extract (%)
In Equation 4, the negative control group is the iNOS expression rate measured after treatment with the stimulant LPS alone, the iNOS expression rate of the extract is the iNOS expression rate measured after treatment with the strawberry stalk extract, and the expression rate is the negative control group It is a value converted to % as a standard.
[Equation 5]
COX-2 expression inhibition ability (%) = COX-2 expression rate of negative control group (%) - COX-2 expression rate of extract (%)
In Equation 5, the negative control group is the COX-2 expression rate measured after treatment with the stimulant LPS alone, and the iNOS expression rate of the extract is the COX-2 expression rate measured after treatment with the strawberry stalk extract, and the expression rate is the measured COX-2 expression rate. 2 It is a value obtained by converting the expression level to % based on the negative control group.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210179088A KR102491188B1 (en) | 2021-12-14 | 2021-12-14 | Manufacturing method of the strawberry stem extracts and Anti-oxidant and anti-inflammatory composition, Health functional foods containing the same and Cosmetics using the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210179088A KR102491188B1 (en) | 2021-12-14 | 2021-12-14 | Manufacturing method of the strawberry stem extracts and Anti-oxidant and anti-inflammatory composition, Health functional foods containing the same and Cosmetics using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102491188B1 true KR102491188B1 (en) | 2023-01-19 |
Family
ID=85078204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210179088A KR102491188B1 (en) | 2021-12-14 | 2021-12-14 | Manufacturing method of the strawberry stem extracts and Anti-oxidant and anti-inflammatory composition, Health functional foods containing the same and Cosmetics using the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102491188B1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006089410A (en) | 2004-09-24 | 2006-04-06 | Aso Seiyaku Kk | Antimicrobial composition |
KR101287021B1 (en) * | 2012-12-31 | 2013-07-17 | 주식회사 제닉 | Cosmetic composition for improving anti-oxidation, anti-inflammatory and atopic skin using supersonic method and manufacturing method thereof |
KR20190045191A (en) | 2016-09-05 | 2019-05-02 | 라보라투와르 클라란스 | The cosmetic use of strawberry fruit extract |
KR20190134233A (en) * | 2018-05-25 | 2019-12-04 | 대한민국(농촌진흥청장) | Composition for anti-oxidation and Anti-inflammation comprising extract of immature Rubus coreanus fruit |
KR20200014633A (en) * | 2018-08-01 | 2020-02-11 | (주)에스앤피인터내셔널 | Compositon for antioxidation comprising strawberry extracts as an active ingredient |
-
2021
- 2021-12-14 KR KR1020210179088A patent/KR102491188B1/en active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006089410A (en) | 2004-09-24 | 2006-04-06 | Aso Seiyaku Kk | Antimicrobial composition |
KR101287021B1 (en) * | 2012-12-31 | 2013-07-17 | 주식회사 제닉 | Cosmetic composition for improving anti-oxidation, anti-inflammatory and atopic skin using supersonic method and manufacturing method thereof |
KR20190045191A (en) | 2016-09-05 | 2019-05-02 | 라보라투와르 클라란스 | The cosmetic use of strawberry fruit extract |
KR20190134233A (en) * | 2018-05-25 | 2019-12-04 | 대한민국(농촌진흥청장) | Composition for anti-oxidation and Anti-inflammation comprising extract of immature Rubus coreanus fruit |
KR20200014633A (en) * | 2018-08-01 | 2020-02-11 | (주)에스앤피인터내셔널 | Compositon for antioxidation comprising strawberry extracts as an active ingredient |
Non-Patent Citations (1)
Title |
---|
Skrovankova et al., Bioactive Compounds and Antioxidant Activity in Different Types of Berries. Int. J. Mol. Sci. 2015, Vol. 16, pp. 24673-24706 1부.* * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007217003B2 (en) | Parthenolide free bioactive ingredients from feverfew (Tanacetum parthenium) and processes for their production | |
KR102016027B1 (en) | Cosmetics composition improving skin wrinkle and skin elasticity and cosmetics including the same | |
KR102232572B1 (en) | Manufacturing method for cosmetic pomposition comprising centella asiatica extract | |
KR20200018879A (en) | Natural cosmetic formulation with excellent effect for skin-microbiome homeostasis and anti-inflammation | |
Bhatnagar et al. | Antioxidant activity of fruit pulp powder of Cassia fistula | |
Varadarajan et al. | Assessing the in vitro antioxidant and anti-inflammatory activity of Moringa oleifera crude extract | |
KR102010404B1 (en) | Cosmetics composition having improvement effect of skin reproduction and cosmetics including the same | |
CN108567632B (en) | Application of tea tree callus extract in skin care | |
KR102483627B1 (en) | Manufacturing method of the strawberry stem extracts and Anti-oxidant and anti-inflammatory inner beauty composition using the same | |
KR102107071B1 (en) | Method for preparing shampoo composition for improving scalp seborrheic dermatitis | |
KR102491188B1 (en) | Manufacturing method of the strawberry stem extracts and Anti-oxidant and anti-inflammatory composition, Health functional foods containing the same and Cosmetics using the same | |
KR101954275B1 (en) | Cosmetic compositions containing complex extract of gold kiwi peel and dragon fruit peel, and method manufacturing the same | |
KR20200128998A (en) | Facturing method of functional liquefied healthfoods using Gastroia elata Blume and Polygonum multiflorum Thunberg | |
KR20160141463A (en) | Anti-oxidation and anti-inflammatory composition comprising the extract of aralia continentalis | |
Przekora et al. | UVB protective, anti-aging, and anti-inflammatory properties of aqueous extract of walnut (Juglans regia L.) seeds | |
KR102471009B1 (en) | Cosmetic composition containing Albiggia kalkora extract for skin whitening and improving wrinkles | |
KR102437871B1 (en) | Composition for preventing or improving of skin wrinkle or skin aging comprising roasted dried-radish-slices extracts, and healthy food comprising the composition | |
KR101793104B1 (en) | Cosmetic composition for whitening skin comprising mixed extract of Cudrania tricuspidata leaf and Morus alba leaf as effective component | |
KR101574248B1 (en) | Cosmetic composition comprising Reynoutria sachalinensis extracts for skin anti-wrinkle effect | |
KR20230039369A (en) | Health functional stick jelly using rose and chrysanthemum extracts | |
Abay et al. | Investigation of Antioxidant Activities of Fruit, Leaf, and Branche Extracts of White (Morus alba L.) and Black (Morus nigra L.) Mulberry Species from Diyarbakır | |
KR20100054772A (en) | The extracts and fractions of Hippophae rhamnoides L. | |
Tenuta et al. | Iridoid-and flavonoid-enriched fractions of Cornus sanguinea and Cornus mas exert antioxidant and anti-inflammatory effects and inhibit key enzymes in the treatment of metabolic disorders | |
KR101966755B1 (en) | Composition for skin-lightening or antioxidant containing extract of Jeju camellia mistletoe | |
KR102551642B1 (en) | A cosmetic composition for improving acne prone skin containing salicylic acid, oregano extract, cucumber grass extract, and bay leaf extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |